Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05418452
Other study ID # 780/439
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date June 15, 2022
Est. completion date June 15, 2023

Study information

Verified date June 2022
Source Al-Azhar University
Contact abdalaziz k aboamo
Phone +201068128254
Email abdel-azizabo-ammo.209@azhar.edu.eg
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aimed to evaluate the efficacy of 1% metformin gel mixed with PRF, in horizontal ridge augmentation with the split-crest technique, for implant placement.


Description:

Dental rehabilitation of edentulous patients with implants has become a common practice in the last few decades. Unfortunately, local conditions of some alveolar ridges of such patients may be challenging for implant placement. One of these conditions is a relevant horizontal deficit that may render dental implants difficult or impossible. Several solutions are presented to overcome this challenge such as different guided bone regeneration (GBR) techniques and horizontal ridge split. However, these techniques have many shortages that may be overcome by the split crest technique (SCT). SCT is a procedure for horizontal bone augmentation. It consists of splitting the vestibular and buccal cortical bone, displacing the vestibular cortical bone both in the maxilla or mandible, and separating from the bone marrow, creating a middle gap that is usually occupied mostly by the inserted implants. In such a procedure, ultrasonic bone surgery represents an advantageous alternative technique over conventional surgery using disks and chisels. The ultrasonic device can safely cut mineralized hard tissues such as bone with minor damage. Additionally, at the bone structural level, ultrasonic bone surgery may increase trabecular density as well as bone compression. To enhance healing the remaining unoccupied space around the implant can be filled with biomaterials such as autologous bone grafts which are considered the gold stander, but unfortunately, site morbidity, as well as, utilizing more than one surgical site may limit its application. Alternatively, other bone substitutes including xenografts, alloplastic, and non-bone graft materials such as Platelet-Rich Fibrin (PRF) have been used in peri-implants space occupation. PRF is a blood derivative in which platelets have a higher concentration above the baseline level. it can regulate inflammation and stimulate the immune process of chemotaxis. This natural material seems to accelerate the physiological wound healing with or without bone grafts to accelerate new bone formation. (6)In clinical practice, it has already been largely applied as an inexpensive carrier and way to obtain many growth factors (GFs) in physiological proportions. Hence, enhanced bone regeneration and favorable implant healing can be better achieved by using PRF as a graft around dental implants. Some authors reported that the use of PRF as a sole filling material during a simultaneous SCT and implantation stabilized a high volume of natural regenerated bone in the spaces unoccupied by the implants. Lately, metformin (MF), an antidiabetic agent, has been successfully used as a local drug delivery agent in periodontitis patients. Literature has suggested that MF possesses the osteogenic potential and induces the growth of osteoblast precursor cells. Therefore, several human studies have reported the use of MF alone or combined with PRF in the treatment of bony defects Although PRF is an autogenous material obtained from a patient's blood and contains GFs which promote bone formation, its short time stability may not give it superiority over a commonly used bone graft like xenograft Adding a medical formula with osteogenic potential such as MF to PRF may add to its therapeutic performance and may present a graft material comparable to bone substitutes with the benefit of being cost-effective. Testing this hypothesis constitutes the primary aim of work in the present clinical study.


Recruitment information / eligibility

Status Recruiting
Enrollment 2
Est. completion date June 15, 2023
Est. primary completion date June 15, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 20 Years to 45 Years
Eligibility Inclusion Criteria: 1. Adults (age 18-50) exhibiting initial insufficiently bone ridge. 2. Patients with good oral hygiene. 3. Free from systemic diseases that may influence the outcome of the therapy. Exclusion Criteria: 1. Heavy smokers. 2. Patient treated by immunosuppressive chemotherapy or radiotherapy, 3. Allergy to any material or medication used in the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Metformin
metformin (MF), an antidiabetic agent, has been successfully used as a local drug delivery agent in periodontitis patients. Literature has suggested that MF possesses the osteogenic potential and induces the growth of osteoblast precursor cells. Therefore, several human studies have reported the use of MF alone or combined with PRF in the treatment of bony defects

Locations

Country Name City State
Egypt AlAzhar universty Cairo

Sponsors (1)

Lead Sponsor Collaborator
Al-Azhar University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary Clinical parameter to measure difference Implant stability (resonance frequency analysis) to detect change from baseline at time (immediately after implant insertion) and after 6 months.
Secondary Radiological assessment to measure difference bone height to detect change from baseline (immediately after surgery), at time of loading (6 months), and 6 months after loading
See also
  Status Clinical Trial Phase
Completed NCT05013580 - The "Open Wound Bone Augmentation Concept" With Amnion-Chorion Membrane N/A
Completed NCT05311332 - Computer-guided vs. Conventional Cortical Shell Technique for Horizontal Augmentation N/A
Completed NCT06043258 - Bond Apatite in Horizontal Augmentation Versus Bio-Oss N/A
Not yet recruiting NCT03635658 - Assessment of GBR in Augmentation of Horizontally Atrophic Maxillary Ridge Using Collagen Membrane Versus Using Titanium Mesh N/A
Completed NCT03153995 - Alveolar Ridge Augmentation Following Self-Inflating Soft Tissue Expander N/A
Not yet recruiting NCT06195761 - Computer Guided Modified Ridge Splitting Versus Free Hand Technique in Horizontal Deficiency in Posterior Mandible N/A
Active, not recruiting NCT03183336 - Horizontal Ridge Augmentation of the Mandible Autogenous Block Grafts N/A
Not yet recruiting NCT06186232 - Evaluation of Bone Regenerated With Guided Bone Regeneration (GBR) Using Polymethylmethacrylate (PMMA) Membrane N/A
Completed NCT04748952 - Ridge Expansion by Osseodensification
Recruiting NCT05813340 - Vascularized Inter-positional Periosteal Connective-tissue Flap Versus Collagen Membrane in Guided Bone Regeneration N/A
Completed NCT04376060 - The Horizontal Ridge Augmentation Using Equine Xenograft and a Collagenated Porcine Cortical Lamina N/A
Completed NCT05286541 - Buccal Cortical Separation and Lateralization for Horizontal Ridge Augmentation N/A